Eli Lilly & Co v Teva Pharmaceutical Industries Limited

External-eyes-only disclosure is exceptional. The disclosing party must show a real risk of misuse causing genuine prejudice, supported by clear and cogent evidence. Restrictions must go no further than necessary after balancing confidentiality against the receiving party’s ability to understand and prepare its case. As trial approaches, relevant documents relied on by experts or witnesses should ordinarily be available to the receiving party’s representatives. An agreed confidentiality order may be varied where it proves unworkable or unfair.

The defendant applied to vary an agreed Confidentiality Order in damages proceedings arising from a settlement agreement concerning the marketing and sale of a patented drug combination. It sought to admit two in-house lawyers to its AEO ring and a senior in-house lawyer with settlement authority to its Confidential ring.

The claimant resisted, relying on the agreed mechanisms for challenging designations and on the sensitivity of its commercial material. The applications were heard shortly before expert evidence, a pre-trial review and trial. The central issues were whether the application was procedurally barred, whether continued exclusion from the AEO ring was justified, and whether the additional Confidential-ring member should be admitted.

1. Jurisdiction and construction. The court had power to vary the agreed Confidentiality Order and to admit further individuals to the AEO club under paragraph 19(f), paragraph 29 and paragraph 15 of Practice Direction 57AD. Paragraphs 8 and 9 provided a permissive re-designation procedure and did not exclude other applications.
2. Applicable principles. The burden rested firmly on Lilly, as the party seeking to maintain the restriction, to establish a real risk of deliberate or inadvertent collateral use and genuine prejudice. Any restriction had to go no further than necessary. The court had to balance confidentiality against Teva’s right to know and prepare its case, considering relevance, the documents’ role at trial, the stage of proceedings, policing difficulties and the receiving party’s ability to contribute.
3. AEO access. Teva’s evidence showed serious prejudice in preparing for trial, understanding the quantum case, obtaining instructions and engaging in settlement. Documents relied on by experts or witnesses were plainly relevant, and access should be given absent clear and cogent justification. Lilly’s general evidence did not establish a sufficient risk of inadvertent disclosure or misuse. The two Teva Lawyers were admitted to the AEO club.
4. Safeguards. One document concerning Lilly’s possible commercial response to generic market entry was temporarily excluded because a potential risk of harm had been shown and its importance to trial was uncertain. The five settlement agreements were to be included unless relevant third parties objected. Access was read-only, with no copying or printing.
5. Further application and appeal. Ms Julie was admitted because she had authority to approve settlement and her involvement supported the overriding objective. Permission to appeal was refused, but the matter was stayed pending any Court of Appeal determination on permission.

This was a first-instance decision. Permission to appeal was refused and the matter was stayed pending the Court of Appeal’s determination of any application for permission.